For US residents only.

Understanding Treatment

Treatment With AFINITOR

What is AFINITOR?

AFINITOR® (everolimus) Tablets is a prescription medicine used to treat adults with advanced kidney cancer (renal cell carcinoma or RCC) when certain other medicines (ie, Sutent® [sunitinib] or Nexavar® [sorafenib]) have not worked. AFINITOR may slow the growth and spread of kidney cancer cells and reduce blood supply to the tumor.

 

If you have taken Sutent® (sunitinib) or Nexavar® (sorafenib) and had to stop because your cancer progressed, AFINITOR might be right for you. AFINITOR is a tablet you take once daily, consistently with or consistently without food.

 

You may take AFINITOR at home or any other place that works for you. This may eliminate the need to receive treatment in your doctor's office. AFINITOR should be taken at the same time every day.

Important Safety Information

Patients should not take AFINITOR if they are allergic to AFINITOR or to any of its ingredients. Patients should tell their health care provider before taking AFINITOR if they are allergic to sirolimus (Rapamune®) or temsirolimus (Torisel®).

Treatment with AFINITOR

  • AFINITOR is a prescription medicine used to treat adults with advanced kidney cancer (renal cell carcinoma or RCC) when certain other medicines (ie, Sutent® [sunitinib] or Nexavar® [sorafenib]) have not worked.
  • AFINITOR is a type of medicine called an mTOR (mammalian target of rapamycin) inhibitor. It is the only mTOR inhibitor approved for the treatment of advanced kidney cancer that is available as a once-daily tablet. It directly affects the cancer in two places–in the cancer cell and in the blood vessels that help feed the cancer cells.* This means that AFINITOR may help make it harder for the cancer to grow and spread to other parts of your body.
* Inhibition of mTOR by everolimus has been shown to reduce cell proliferation, angiogenesis, and glucose uptake in preclinical and clinical studies.

How AFINITOR works

Understanding how AFINITOR works

The way AFINITOR works, also called its mechanism of action (MOA), is different from some other medications. AFINITOR affects the cancer in two places*:

  • The cancer cells
  • The blood vessels that help feed the cancer cells

As a result, AFINITOR:

  • May slow the growth and spread of kidney cancer
  • Can restrict cancer cells from getting the nutrition they need to grow
  • May slow the blood vessels from growing and supplying the tumor with blood

 

AFINITOR may also affect healthy, nontumor cells

* Inhibition of mTOR by everolimus has been shown to reduce cell proliferation, angiogenesis, and glucose uptake in preclinical and clinical studies.